The Latest Breaking News from FDA

A federal appeals court in New Orleans has revived a lawsuit by three doctors who say the Food and Drug Administration overstepped its authority in a campaign against the use of a drug that is not approved to treat COVID-19

Drugs and medical devices rarely come from the nonprofit world

Detroit's forfeiture machine, major nuclear questions, and copyrightable materials.

Advanced medical technologies and the pivotal role of technology in drug development are poised to drive significant growth in the biotech industry. Against this backdrop, should you buy, sell or hold biotech stocks Moderna (MRNA), MacroGenics (MGNX), and Amicus Therapeutics (FOLD)? Let’s find out….

Although it would leave federal prohibition essentially untouched, the change would facilitate medical research and dramatically reduce taxes on state-licensed suppliers.

Plus: Tennessee prosecutor threatens to use drag law that was declared unconstitutional, ACLU asks FTC to investigate Mastercard's adult content policy, and more...

Soaring demand for two weight-loss wonder-drugs developed by a Danish pharmaceutical company is having a knock-on effect on the whole of Denmark’s economy.

Sesame is now the 9th official allergen. The FDA designation was supposed to protect people with sesame allergies. Instead, it's become harder to avoid, as more bakers add sesame to their products.

The U.S. Court of Appeals for the D.C. Circuit takes issue with how the FDA evaluated Fontem's unflavored vaping products.

With innovative approaches and cutting-edge technologies, biotech has ushered in a new era of possibilities in the medical field. Hence, investing in three fundamentally sound biotech stocks, Equillium, Inc. (EQ), Theratechnologies (THTX), and Exelixis (EXEL), could yield healthy profits. Learn more….

Abrysvo was also approved by the FDA in May 2023 to prevent RSV illness in adults 60 years and older